The Royal National Institute of Blind People (RNIB), a UK charity, has announced it will support the legal battle by an 84-year old man to have access to Swiss drug major Novartis' Lucentis (ranibizumab). The decision follows the controversy over a ruling by the National Institute for Health and Clinical Excellence to recommend that the drug should only be made available to National Health Service patients in restricted circumstances (Marketletter June 25).
Steve Winyard, an RNIB spokesman, told the BBC that the Oxfordshire Primary Care Trust, which claims to consider cases individually, had yet to authorize the drug to a patient.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze